首页> 外文OA文献 >Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
【2h】

Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.

机译:通过使用基于牛痘的瞬时表达系统,在人P-糖蛋白中甘氨酸185-缬氨酸取代的功能表征。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human P-glycoprotein (Pgp) is a 170-kDa plasma membrane protein that confers multidrug resistance to otherwise sensitive cells. A mutation in Pgp, G185-->V, originally identified as a spontaneous mutation, was shown previously to alter the drug resistance profiles in cell lines that are stably transfected with the mutant MDR1 cDNA and selected with cytotoxic agents. To understand the mechanism by which the V185 mutation leads to an altered drug resistance profile, we used a transient expression system that eliminates the need for drug selection to attain high expression levels and allows for the rapid characterization of many aspects of Pgp function and biosynthesis. The mutant and wild-type proteins were expressed at similar levels after 24-48 h in human osteosarcoma (HOS) cells by infection with a recombinant vaccinia virus encoding T7 RNA polymerase and simultaneous transfection with a plasmid containing MDR1 cDNA controlled by the T7 promoter. For both mutant and wild-type proteins, photolabeling with [3H]azidopine and [125I]iodoarylazidoprazosin, drug-stimulated ATPase activity, efflux of rhodamine 123, and accumulation of radiolabeled vinblastine and colchicine were evaluated. In crude membrane preparations from HOS cells, a higher level of basal Pgp-ATPase activity was observed for the V185 variant than for the wild-type, suggesting partial uncoupling of drug-dependent ATP hydrolysis by the mutant. Several compounds, including verapamil, nicardipine, tetraphenylphosphonium, and prazosin, stimulated ATPase activities of both the wild-type and mutant similarly, whereas cyclosporin A inhibited the ATPase activity of the mutant more efficiently than that of the wild-type. This latter observation explains the enhanced potency of cyclosporin A as an inhibitor of the mutant Pgp. No differences were seen in verapamil-inhibited rhodamine 123 efflux, but the rate of accumulation was slower for colchicine and faster for vinblastine in cells expressing the mutant protein, as compared with those expressing wild-type Pgp. We conclude that the G185-->V mutation confers pleiotropic alterations on Pgp, including an altered basal ATPase activity and altered interaction with substrates and the inhibitor cyclosporin A.
机译:人P糖蛋白(Pgp)是170 kDa的质膜蛋白,对其他敏感细胞具有多重耐药性。 Pgp中的G185-> V突变最初被确定为自发突变,先前已显示出它可以改变被突变MDR1 cDNA稳定转染并被细胞毒性剂选择的细胞系的耐药性。为了了解V185突变导致耐药性改变的机制,我们使用了一种瞬时表达系统,该系统无需进行药物选择即可获得高表达水平,并可以快速表征Pgp功能和生物合成的许多方面。通过用编码T7 RNA聚合酶的重组牛痘病毒感染并同时用含有受T7启动子控制的MDR1 cDNA的质粒转染,在人骨肉瘤(HOS)细胞中24-48小时后,突变蛋白和野生型蛋白以相似的水平表达。对于突变型蛋白和野生型蛋白,均评估了[3H]叠氮平和[125I]碘代芳基叠氮吡唑嗪的光标记,药物刺激的ATPase活性,若丹明123的外排以及放射性标记的长春碱和秋水仙碱的积累。在从HOS细胞制备的粗制膜中,观察到V185变体比野生型具有更高水平的基础Pgp-ATPase活性,表明该突变体使药物依赖性ATP水解部分解偶联。几种化合物,包括维拉帕米,尼卡地平,四苯基phosph和哌唑嗪,类似地刺激野生型和突变体的ATPase活性,而环孢菌素A抑制突变体的ATPase活性比野生型更有效。后一个观察结果解释了环孢菌素A作为突变体Pgp抑制剂的效力增强。与表达野生型Pgp的细胞相比,在表达突变蛋白的细胞中,维拉帕米抑制的若丹明123流出没有差异,但是秋水仙碱的蓄积速度较慢,长春碱的蓄积速度较快。我们得出的结论是,G185-> V突变赋予Pgp多效性改变,包括基础ATPase活性改变以及与底物和抑制剂环孢菌素A的相互作用改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号